Index

abnormal test results 6
accuracy 20–1
additional cost per life year granted 113
adoption studies 48
aetiological cohorts 86
aetiology 4, 11, 167
age distribution 16
ageing 195–6
alleles 47–8
allocation concealment 95–6
all-the-time targets 185
anaemia 7–8
analogy 57
annuitisation 115
ascertainment 16
assent 124
association 55–6
  specificity of 58
  strength of 57
association analysis 49
association between two variables 17
  absolute and relative 17–19
association studies, genome-wide (GWAS) 50–1
asthma 23–4
attributable risk 17
audit 120
audit cycle 121
averages 12
bar charts 6
baseline comparisons 96
basic reproduction number 153
  factors influencing 156
behaviour change to improve health 174
  brief interventions 174
bias in epidemiological studies 21, 39, 56
detection bias 96
differential misclassification 22
differential selection 22
language bias 108
loss to follow up bias 43, 88–9, 96–7
measurement bias 22, 96
nondifferential misclassification 22
nondifferential selection 21–2
nonresponse and recall bias 115
performance bias 96
progression bias 81
publication bias 108
recall bias 43
referral bias 88
reporting bias 39
selection bias 21, 81, 95
sequential ordering bias 81
specificity of association 57
strength of association 57
stem 57
successive ordering bias 81
work-up bias 81
bimodal curve 8
bimodal distribution 12
binary variables 12
biological gradient 57
blinding 96
brief interventions 174
burden of infectious disease 152
candidate gene association studies 49
carrier state 153
case definition 39, 156–7
  as clinical syndrome 7–8
  as disease risk (prognostic) 6–7
  as unusual (statistical) 5–6
case fatality 86
case series 14, 37
case-control studies 21, 39–40
  selecting best control 40
categorical variables 11–12
causal links 6
causality 55–6
  conditions for 56–7
cross-cohort comparisons 59
Mendelian randomisation studies 59–60
parental–offspring comparisons 58–9
population level causality 60–1
sensitivity analysis 58
  specificity of association 58
  with and between sibling comparisons 59
censored patients 86
central tendency 12
chance 16, 56
children
  ethical issues 123–4
  nutrition and health 193–4
Chronic Fatigue Syndrome 8–9
clinical epidemiology 4, 69
clinical equipoise 99, 122
clinical iceberg 38
clinical outcomes 95
Cochrane collaboration database 72
Cochrane review 138
coding 17
coherence 57
cohort studies 7, 21, 40–2, 175
  aetiological cohorts 86
  cross-cohort comparisons 59
diagnostic cohort 80
  prognostic cohorts 87

© 2013 Y. Ben-Shlomo, S. T. Brookes and M. Hickman. Published 2013 by John Wiley & Sons, Ltd.
| communicable diseases 145, 152 |
| global health 192–3 |
| complex diseases 47–8 |
| genetic testing 52–3 |
| complex interventions |
| cluster randomised trials 178 |
| advantages and disadvantages 179 |
| rationale 178 |
| definition 177 |
| mixed methods and qualitative methodology 181 |
| stepped wedge design 178–9 |
| composite outcomes 95 |
| confidence interval 95% confidence interval 29 |
| P-values 34 |
| population mean 29 |
| population proportion 30 |
| confounding in epidemiological studies 22–3, 93 |
| controlling for 23 |
| controlling for number of confounders 24 |
| controlling in study analysis 23–4 |
| disease causes 56 |
| example 23 |
| quality of adjusted results 25 |
| reporting analysis results 24–5 |
| consent, informed 99, 122, 123 |
| consistency 57 |
| contamination 178 |
| continuous variables 11 |
| control groups 94 |
| control selection 40 |
| Cost Benefit Analysis (CBA) 116 |
| Cost Consequences Study (CCS) 115–16 |
| cost effectiveness acceptability curve (CEAC) 118, 119 |
| Cost Effectiveness Analysis (CEA) 115 |
| cost-effective interventions 174 |
| Cost-Effectiveness Plane (CEP) 116 |
| Cost-Utility Analysis (CUA) 116 |
| cot death (SIDS) 141–2 |
| critical incident analysis 120 |
| cross-sectional studies 93, 100 |
| cross-sectional studies 21, 22, 38–9 |
| cumulative incidence (risk) 15–16 |
| databases 72 |
| decision analysis models 114 |
| Declaration of Helsinki 122 |
| demography 16 |
| detection bias 96 |
| determinants of health 171–2 |
| diagnosis 74–82 |
| applicability to patients 82 |
| definition 74 |
| evidence-based 75 |
| likelihood ratio (LR) 78–9 |
| study accuracy 82 |
| study trustworthiness 79–80 |
| study trustworthiness 80–2 |
| diagnostic case control 80–1 |
| diagnostic cohort 80 |
| diagnostic techniques 16 |
| diagnostic test |
| definition 74–5 |
| evaluation 75 |
| index test 81 |
| patient flow 81 |
| positive and negative predictive values 77 |
| pre-test probability of target condition 77 |
| reference standard 81 |
| dichotomous variables 12 |
| difference in means 17 |
| differential misclassification 22 |
| differential prognostic factors 88 |
| differential selection 22 |
| disability adjusted life years (DALYs) 192 |
| discrete variables 11 |
| disease causes |
| association and causality 55–6 |
| causality at population level 60–1 |
| conditions for causality 56–7 |
| examining causality 57–60 |
| definition 4 |
| mapping 49–50 |
| progression bias 81 |
| disease-specific questionnaires 95 |
| dizygotic (nonidentical) twins 48 |
| comparisons between 59 |
| dominant disease/phenotype 47–8 |
| ecological fallacy 38, 179 |
| ecological studies 37–8, 161 |
| advantages and disadvantages 180 |
| effect modification 24 |
| effective reproduction number 154 |
| effectiveness of treatments |
| clinical experience 92–3 |
| RCTs biases 95–7 |
| essential steps 93 |
| inclusion/exclusion criteria 94 |
| intervention and control groups 94 |
| outcome measures 95 |
| qualitative methods 98–9 |
| relative risk and number needed to treat 97–8 |
| sample size calculation 94 |
| efficiency 113 |
| elimination 155 |
| empowerment and social change 175 |
| endemic diseases 155 |
| environment 197–8 |
| environmental and social change 137 |
| epidemic curve 157, 158 |
| epidemics 154 |
| epidemiology |
| case definition in studies 8–9 |
| definition 3–4 |
| descriptive 16–17 |
| disease 4 |
| life course 167 |
| sociocultural perspective 5 |
| eradication 155 |
| estimating population statistics 26–7 |
| blood pressure 27–9 |
| comparing two means 30–1 |
comparing two means in small samples 31–2
comparing two proportions 32
population proportion 29–30
population proportion confidence interval 30
ethical issues 121–2
health improvement 171
informed consent 123
observational studies 123
RCTs 99–100, 122–3
vulnerable groups
children 123–4
incapacitated adults 124–5
evidence-based medicine (EBM) 69, 113, 136
definition 69–70
domains 70–1
evidence for changing practice 71
example questions 71
misperceptions 70
stages 71–2
exclusion 86, 94
experiment 57
experimental study 36
exposure 17, 36, 55
Fagan’s nomogram 78, 79
false negative results 76
false positive results 50, 76
fasting glucose levels 7
fixed effect 105
flow diagram 89
forest plots 106
FRAMES motivational interviewing techniques 174
Framingham Heart Study 4
Framingham risk equation 4
funnel plots 108
Gaussian (normal) distributions 6, 13–14
gender health inequalities 164–5
generalsity 72, 94
genetic questionnaires 95
genes 46
genetic epidemiology
definition 46
disease mapping 49–50
genome-wide association studies (GWAS) 50–1
monogenic versus polygenic diseases 47–8
next generation sequencing (NGS) 53–4
novel techniques 47
pharmacogenomics 53
twin, adoption and migrant studies 48–9
genetic testing
complex diseases 52–3
monogenic diseases 51–2
genome-wide sequencing 51
genomic profiling 52
genotype 49
geographical health inequalities 162–4
global health
burden of death and disability 191–2
communicable diseases 192–3
definition 191
environment 197–8
global solutions 199–200
globalisation 197
maternal and child health 193
nutrition and health 193–4
migration 197
noncommunicable diseases (NCDs) 194–5
injuries 195
population ageing and urbanisation 195–6
negative effects 196
positive effects 196–7
reinventing primary health care 200
wider determinants
social inequalities 198–9
Haddon Matrix 140
health care evaluation 11
health care targets 189–90
characteristics of good targets 188–9
definition 184–5
history 185–6
problems 187
public health policy 184
value 186–7
health economics
cost 115
economic context of health decisions 112–13
economic evaluation 112
design 113–14
recommendations 119
result interpretation 118
results 116–17
efficiency 114
QALY definition 116
value for money 115–16
Health Impact Assessment (HIA) 136
health improvement
behaviour change 174
brief interventions 174
definition 170–1
determinants of health 171–2
empowerment and social change 175
ethics 171
high-risk and population approaches to prevention 172–4
medical practice 175–6
tobacco control 175
health inequalities see inequalities in health
Health Inequality Impact Statement 168
health promotion 170
health protection 136
health-care economic outcomes 95
herd immunity 154
herd immunity threshold 154
heritability of a trait 48
heterogeneity 88, 106
hierarchy of evidence 36, 69, 93
histograms 6
Human Genome Project 47
hypothesis 17
investigating 32–3
I² statistic 107
identical (monozygotic) twins 48
comparisons between 59
identification of resources 115
immunity 153
imputation 89
incapacitated adults, ethical issues 124–5
incidence rate 15
inclusion 94
incremental Cost Effectiveness Ratio (ICER) 117
incubation period 153
Index of Multiple Deprivation 161
index test 75
inequalities in health
definitions 160–1
life course inequalities 166–7
measuring inequalities 161
gender health inequalities 164–5
geographical health inequalities 162–4
race and ethnicity health inequalities 165–6
socioeconomic health inequalities 161–2
reducing inequality gap 167–8
relative versus absolute inequalities 166
infectious disease 152–3
characteristics 153
control 155
occurrence 154–5
surveillance 155–6
outbreak investigation 156–8
transmission 153–4
modes 154
informed consent 99, 122, 123
injuries 195
intention to treat analysis (ITT) 96–7
interaction 24
interquartile range 13
intervention groups 94
intervention studies, compared with observational studies 36–7
inverse variance 106
interviewing techniques, motivational 174
Joint Strategic Needs Assessment 138
Kaplan–Meier graph 86, 87
language bias 108
latency period 56
latent period 153
life course epidemiology 167
life course inequalities 166–7
likelihood ratio (LR) 75, 78–9, 148
linkage analysis 49
linkage disequilibrium 47
logistic regression 24
loss to follow up bias 43, 88–9, 96–7
Mantel–Haenszel methods 24
mean 6, 12, 14
comparing two means 30–1
comparing two means in small samples 31–2
confidence interval 29
measurement bias 22, 96
measurement of patient use 115
median 12
medical advances 137
Mendelian diseases 47–8
Mendelian randomisation studies 59–60
menstruation 7–8
meta analysis 105–6
forest plots 106
heterogeneity between study results 106–7
meta-regression analysis 105
migrant studies 48
migration 197
Millennium Development Goals 185, 200
missing heritability 51
mixed methods 181
mode 12
monogenic diseases 47–8
genetic testing 51–2
monozygotic (identical) twins 48
comparisons between 59
moral hazard 113
mortality rate 86
motivational interviewing techniques 174
MPOWER framework 175
multimodal distribution 12
multivariable models 24
National Institute for Health and Clinical Excellence (NICE) 72
natural experiments 180–1
Negative Predictive Value (NPV) 77
Net Monetary Benefit (NMB) 117
Never Events 185
next generation sequencing (NGS) 53–4
noncommunicable diseases (NCDs) 194–5
injuries 195
nondifferential misclassification 22
nondifferential selection 21–2
nonidentical (dizygotic) twins 48
comparisons between 59
nonresponse bias 115
normal (Gaussian) distributions 6, 13–14
notifiable diseases 157
Nuffield Council on Bioethics ladder of public health intervention 171
null hypothesis 17, 33, 34
number needed to treat 70
RCTs 97–8
number needed to treat to benefit (NNTB) 98
number needed to treat to harm (NNTH) 98
numerical variables 11
nutrition and health 193–4
observational studies
advantages and disadvantages 42–4
compared with intervention studies 36–7
designs 37–42
ethical issues 123
odds of disease 18
odds ratio 18
on treatment analysis 97
opportunity cost 114
ordered categorical variables 12
outbreaks 154
investigating 156–8
outcomes 17, 84–5
clinical 95
composite 95
health-care economic 95
patient reported (PROs) 95, 115
RCTs 95
surrogate 95
P-value 33
  confidence intervals 34
  interpretation 33–4
pandemics 154–5
parental–offspring comparisons 58–9
participant confidentiality 122
patient flow 81
patient reported outcomes (PROs) 95
Patient, Intervention, Comparator, Outcome (PICO) tool 113
percentage achievement targets 185
performance bias 96
per-protocol analysis 97
pharmacogenomics 53
phenotype 49
placebo 93
plausibility 57
polygenic diseases 47–8
  genetic testing 52–3
  population ageing 195–6
  population attributable risk 17
  population epidemiology 4
  population proportion estimation 29–30
  comparing two proportions 32
  confidence interval 30
Positive Predictive Value (PPV) 77, 148
Post-viral Fatigue Syndrome 9
prediction 20–1
predictive values 75
pre-test probability 77
prevalence 15, 87
prevention paradox 173
primary prevention 93, 137
prognosis
  definition 84
  outcomes 84–5
  prognostic risk factors 85
  displaying, summarising and quantifying 85–6
  prognostic studies 85–6
    design 86–7
    generalisability 87–8
    long-term 89–90
    loss to follow-up bias 88–9
    short-term 89
  prognostic cohorts 87
  proportion 15
  public health 142, 186
    action 140
      SIDS prevention 141–2
      suicide prevention 140–1
    definition 135
    diagnosis 137–8
    interventions 138–9
    practice 135–6
Public Health Improvement Ladder 171
Public Health Intervention Ladder 139
public health policy 184
publication bias 108
Q-statistic 107
qualitative research methods 181
  qualitative targets 185
  quantitative studies 11
  Quality Adjusted Life Years (QALYs) 116
    definition 116
    quality of life 84
race and ethnicity health inequalities 165–6
random effects 106
  analysis 107
  random errors 22
  random fluctuations 16
randomisation 96
randomised controlled trial (RCT) 21, 36
  cluster randomised trials 178
  complex interventions 177
  ethical issues 122–3
  reasons not to undertake 180
  screening 148
  stepped wedge design 178–9
randomised controlled trials (RCT) 93
  biases 95
    allocation concealment 95–6
    loss to follow-up bias and intention to treat analysis 96–7
    measurement bias and blinding 96
    selection bias 95
  cluster randomised trials 100, 178
  advantages and disadvantages 179
  rationale 178
  essential steps 93
  ethical issues 99–100
  inclusion/exclusion criteria 94
  intervention and control groups 94
  other types 100
  outcome measures 95
  qualitative methods 98–9
  relative risk and number needed to treat 97–8
  sample size calculation 94
range 13
ratio 113
recall bias 43, 115
recessive disease 47–8
reference ranges 6, 14
reference standard 75, 81
referral bias 88
regression models 24
relative risk 18, 48, 88
  reliability (precision) 20–1
  reporting bias 39
  research governance 125–5
  residual confounding 25
  reverse causality 39, 56
  risk difference (RD) 17, 98
  risk factors 36
  risk ratio (RR) 18, 98
  samples 6, 11, 26
  sampling distribution 28
  screening 74
  benefit and harm 147
  controlled trials 147–8
  definition 146
screening (Continued)
  good service to patients 148–9
  history 145
secondary prevention 148
selected sample 38
selection bias 21, 81, 95
selective reporting of outcomes 108
sensitivity 53, 75–6
sensitivity analysis 58, 105, 119, 148
sequential ordering bias 81
service evaluation 121
sibling comparisons 59
single nucleotide polymorphisms (SNPs) 47, 50
skewed distribution 27
SMART criteria 188–9
SnNout 76
social inequalities 198–9
societal class 161
societal viewpoint 114
sociocultural perspective on epidemiology 5
socioeconomic health inequalities 161–2
socioeconomic position (SEP) 161
socioeconomic status 161
specificity 53, 57, 75–7, 148
specificity of association 58
spectrum bias 81
SpPin 76
spread of values 12
standard deviation (SD) 13–14
standard error 28, 29
standardisation 23–4
standardised format 105
standardised mean difference 105
statistical process control 121
step function 86
stepped wedge design 178–9
stratification 24
strength of association 57
studies of studies 102
study samples 11, 39
Sudden Infant Death Syndrome (SIDS) 141–2
supplier induced demand 113
surrogate outcomes 95
survival analysis 86
survival rate 86
symptom-specific measures 95
systematic errors 22
systematic reviews 71, 102–3
critical appraisal 110
presenting results of review 108–10
procedure 103
assessing quality of included studies 104–5
defining review question and inclusion criteria
  103
extracting relevant data 104
identifying relevant studies 103–4
meta analysis 105–6
forest plots 106
heterogeneity between study results 106–7
reporting biases 108
target population 11, 26, 38
technical efficiency 115
technically and allocatively efficient 116
temporality 57
test for heterogeneity 107
test performance 148
time horizon 114
Time, Place, Person (TPP) descriptions 16
time-bound targets 185
tobacco control 175
transmission modes for infectious diseases 154
treatment effects 17
true negative result 76
true positive result 76
twin studies 48
type I errors 50
underpowered studies 94
unimodal curve 8
unimodal distribution 12
unordered categorical variables 12
urbanisation 195–6
utilities 70
vaccines 155
validity (accuracy) 20–1
valuation of resources 115
valuation of services 115
variability 12, 13
variables 11
association between two variables 17–19
binary variables 12
categorical variables 11–12
dichotomous variables 12
numerical variables 11
ordered categorical variables 12
unordered categorical variables 12
verification bias 81
vulnerable groups
  children 123–4
  incapacitated adults 124–5
willing to pay (WTP) 116
Wilson’s Criteria 145
work-up bias 81
z test statistic 33–4